Table 1.
Total population (n = 125) | Ischemia (n = 66) | No ischemia (n = 59) | p | |
---|---|---|---|---|
Clinical characteristics | ||||
Age (years) | 62 ± 9 | 63 ± 9 | 62 ± 9 | 0.355 |
Female sex | 72 (58%) | 36 (55%) | 36 (61%) | 0.465 |
BMI (kg/m2) | 27.6 ± 4.5 | 27.1 ± 4.1 | 28.1 ± 4.9 | 0.247 |
Obesity | 28 (22%) | 10 (15%) | 18 (31%) | 0.040 |
Hypertension | 92 (74%) | 53 (80%) | 39 (67%) | 0.097 |
Diabetes | 17 (14%) | 8 (13%) | 9 (16%) | 0.862 |
Current smoker | 18 (14%) | 8 (12%) | 10 (17%) | 0.445 |
Family history of premature CAD | 71 (57%) | 34 (52%) | 37 (63%) | 0.139 |
Chest pain ≥ 6 months | 94 (75%) | 50 (76%) | 44 (75%) | 0.879 |
Dyspnea ≥ 6 months | 83 (66%) | 44 (67%) | 39 (66%) | 0.947 |
Systolic blood pressure (mmHg) | 134 ± 16 | 134 ± 16 | 135 ± 16 | 0.774 |
Diastolic blood pressure (mmHg) | 78 ± 13 | 78 ± 12 | 78 ± 13 | 0.927 |
Heart rate (bpm) | 65 ± 12 | 66 ± 11 | 63 ± 12 | 0.167 |
HbA1c (mmol/mol) | 39 ± 9 | 39 ± 7 | 39 ± 10 | 0.986 |
Estimated GFR (mL/min/1.73 m2) | 86 ± 14 | 87 ± 15 | 84 ± 13 | 0.292 |
Total serum cholesterol (mmol/L) | 5.1 ± 1.3 | 5.1 ± 1.4 | 5.0 ± 1.1 | 0.780 |
Serum HDL cholesterol (mmol/L) | 1.5 ± 0.4 | 1.5 ± 0.5 | 1.5 ± 0.4 | 0.850 |
Serum LDL cholesterol (mmol/L) | 3.3 ± 1.2 | 3.3 ± 1.3 | 3.2 ± 1.0 | 0.791 |
Serum triglycerides (mmol/L) | 1.48 ± 0.98 | 1.56 ± 0.85 | 1.40 ± 1.11 | 0.327 |
Medical therapy | ||||
Acetylsalicylic acid | 51 (41%) | 32 (49%) | 19 (32%) | 0.027 |
Statin | 46 (37%) | 25 (38%) | 21 (36%) | 0.543 |
Antihypertensive treatment | 64 (51%) | 34 (52%) | 30 (51%) | 0.663 |
Beta blocker | 34 (27%) | 14 (21%) | 20 (34%) | 0.154 |
Calcium channel blocker | 21 (17%) | 15 (23%) | 6 (10%) | 0.056 |
Angiotensin converting enzyme inhibitor | 8 (6%) | 4 (6%) | 4 (7%) | 0.936 |
Angiotensin 2 receptor inhibitor | 38 (30%) | 25 (38%) | 13 (22%) | 0.039 |
BMI, body mass index; CAD, coronary artery disease; bpm, beats per minute; HbA1c, hemoglobin A1c, GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.